Brokerages expect Amgen, Inc. (NASDAQ:AMGN) to report earnings per share (EPS) of $3.04 for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Amgen’s earnings, with estimates ranging from $2.92 to $3.18. Amgen posted earnings per share of $2.89 during the same quarter last year, which suggests a positive year over year growth rate of 5.2%. The business is scheduled to announce its next quarterly earnings report after the market closes on Thursday, February 1st.

On average, analysts expect that Amgen will report full year earnings of $12.71 per share for the current year, with EPS estimates ranging from $12.61 to $12.91. For the next year, analysts forecast that the company will report earnings of $12.75 per share, with EPS estimates ranging from $10.93 to $13.83. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Amgen.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company’s quarterly revenue was down .7% on a year-over-year basis. During the same period last year, the company earned $3.02 EPS.

A number of brokerages recently issued reports on AMGN. Oppenheimer set a $205.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets reissued a “hold” rating and set a $199.00 price objective on shares of Amgen in a research report on Monday, September 25th. Vetr downgraded Amgen from a “buy” rating to a “hold” rating and set a $184.25 price objective for the company. in a research report on Wednesday, January 3rd. Piper Jaffray Companies restated a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Finally, Credit Suisse Group restated a “neutral” rating and set a $186.00 target price (up from $177.00) on shares of Amgen in a report on Friday, September 29th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $190.15.

Shares of Amgen (AMGN) opened at $185.04 on Friday. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $134,320.00, a PE ratio of 16.72, a P/E/G ratio of 2.66 and a beta of 1.36. Amgen has a 52-week low of $150.38 and a 52-week high of $191.10.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 2.85%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is presently 41.55%.

Amgen declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the completion of the transaction, the executive vice president now owns 56,106 shares in the company, valued at approximately $9,921,223.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders sold a total of 7,050 shares of company stock valued at $1,225,765 in the last quarter. Company insiders own 0.19% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Baker Ellis Asset Management LLC purchased a new stake in Amgen during the third quarter worth approximately $108,000. Phocas Financial Corp. purchased a new stake in Amgen during the second quarter worth approximately $110,000. Jackson Grant Investment Advisers Inc. lifted its stake in Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the last quarter. Omnia Family Wealth LLC lifted its stake in Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares during the last quarter. Finally, Grove Bank & Trust lifted its stake in Amgen by 87.4% during the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after purchasing an additional 341 shares during the last quarter. Institutional investors and hedge funds own 78.46% of the company’s stock.

WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/14/zacks-analysts-anticipate-amgen-inc-amgn-to-announce-3-04-eps.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Get a free copy of the Zacks research report on Amgen (AMGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.